Quantcast

Latest Andrew Witty Stories

b5585972c9c875568f89c3ae6438d9101
2009-02-15 07:37:54

According to the head of British pharmaceutical giant GlaxoSmithKline, the company will begin sharing knowledge of patented treatments, and will cut prices for medication in developing nations. Andrew Witty, in an interview with the British newspaper Guardian, said he believed pharmaceutical companies had an obligation the help treat the poor, and has challenged his competitors to do the same. "We work like crazy to come up with the next great medicine, knowing that it's likely to get used an...

2009-02-05 07:25:00

LONDON, February 5 /PRNewswire-FirstCall/ -- In a video interview Andrew Witty, GlaxoSmithKline CEO, described the pharmaceutical group's results as "robust" in a year that was "always going to be challenging". GSK also announced that it will cease providing EPS guidance, to allow a focus on longer term strategic goals. Describing 2008 as a strategic turning point for GSK Mr Witty said: "We started to make very clear what it would take to really make this company strong over the...

2009-01-29 15:31:00

PHILADELPHIA, Jan. 29 /PRNewswire-FirstCall/ -- On Thursday, February 5th, GlaxoSmithKline plc (NYSE: GSK) will announce its year end financial results for the year ended December 31, 2008. The announcement is scheduled for release to the London Stock Exchange at approximately 7:00 AM Eastern Standard Time (EST). At 9:00 AM EST Andrew Witty, Chief Executive Officer, and Julian Heslop, Chief Financial Officer will hold a briefing meeting for analysts and investors. The meeting is available...

2008-07-21 12:01:26

Biota Holdings Limited (ASX: BTA) today announced it had concluded its litigation against GlaxoSmithKline (GSK). The announcement followed formal mediation between by the parties ordered by the Victorian Supreme Court. The mediation provided the parties with the opportunity to resolve their differences and eliminate the uncertainty and costs associated with the legal process. Biota and GSK have agreed to normalise their relationship to pursue the best interests of Relenza, with senior...

2006-02-01 09:25:00

By Ben Hirschler, European Pharmaceuticals Correspondent LONDON -- GlaxoSmithKline Plc continued its roll-out of new products on Wednesday, winning fresh regulatory approvals for two niche treatments to fight diabetes and cancer. Europe's biggest drug maker said it was launching Avandaryl, a two-in-one diabetes pill, in the United States and had been given a green light in Europe to market Hycamtin -- already used to fight ovarian tumors -- as a treatment for lung cancer. Both approvals had...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related